Bruker Corporation (BRKR) Given Hold Rating at Cowen and Company
Cowen and Company reissued their hold rating on shares of Bruker Corporation (NASDAQ:BRKR) in a research note published on Friday. They currently have a $29.00 target price on the medical research company’s stock.
A number of other analysts have also recently commented on the stock. Wells Fargo & Company cut shares of Bruker Corporation from a market perform rating to an underperform rating in a research note on Wednesday, July 12th. Zacks Investment Research upgraded shares of Bruker Corporation from a hold rating to a buy rating and set a $33.00 target price for the company in a research note on Thursday, July 6th. Jefferies Group LLC reiterated a buy rating and issued a $29.00 target price on shares of Bruker Corporation in a research note on Monday, May 15th. Deutsche Bank AG lifted their target price on shares of Bruker Corporation from $25.00 to $27.00 and gave the stock a hold rating in a research note on Monday, May 15th. Finally, Cleveland Research upgraded shares of Bruker Corporation from a neutral rating to a buy rating in a research note on Thursday, April 27th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $26.46.
Bruker Corporation (NASDAQ:BRKR) traded up 0.66% on Friday, hitting $29.18. 314,532 shares of the stock traded hands. The company has a market capitalization of $4.66 billion, a PE ratio of 30.98 and a beta of 1.10. The firm has a 50-day moving average price of $27.44 and a 200-day moving average price of $24.28. Bruker Corporation has a 12 month low of $19.58 and a 12 month high of $30.02.
Bruker Corporation (NASDAQ:BRKR) last released its earnings results on Wednesday, May 3rd. The medical research company reported $0.19 EPS for the quarter, hitting analysts’ consensus estimates of $0.19. The company had revenue of $384.90 million during the quarter, compared to analysts’ expectations of $372.59 million. Bruker Corporation had a net margin of 9.35% and a return on equity of 26.88%. Bruker Corporation’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period last year, the business earned $0.21 EPS. Analysts forecast that Bruker Corporation will post $1.10 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Bruker Corporation (BRKR) Given Hold Rating at Cowen and Company” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/07/17/bruker-corporation-brkr-given-hold-rating-at-cowen-and-company.html.
Bruker Corporation declared that its board has initiated a share repurchase program on Friday, May 12th that allows the company to buyback $225.00 million in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.
The firm also recently declared a quarterly dividend, which was paid on Friday, June 23rd. Shareholders of record on Monday, June 5th were given a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date of this dividend was Thursday, June 1st. Bruker Corporation’s dividend payout ratio is presently 17.02%.
In other news, Director Ingen Chris Van sold 19,900 shares of Bruker Corporation stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $28.03, for a total transaction of $557,797.00. Following the completion of the transaction, the director now directly owns 14,577 shares of the company’s stock, valued at approximately $408,593.31. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Richard Kniss sold 24,000 shares of Bruker Corporation stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $28.23, for a total transaction of $677,520.00. Following the transaction, the director now directly owns 46,753 shares of the company’s stock, valued at $1,319,837.19. The disclosure for this sale can be found here. Over the last three months, insiders have acquired 78,120 shares of company stock valued at $2,047,366 and have sold 117,624 shares valued at $3,271,574. Company insiders own 35.80% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Canada Pension Plan Investment Board raised its position in Bruker Corporation by 648.9% in the first quarter. Canada Pension Plan Investment Board now owns 70,400 shares of the medical research company’s stock valued at $1,642,000 after buying an additional 61,000 shares during the period. Highbridge Capital Management LLC purchased a new position in Bruker Corporation during the first quarter valued at $6,030,000. Parametrica Management Ltd purchased a new position in Bruker Corporation during the first quarter valued at $309,000. Denver Investment Advisors LLC raised its position in Bruker Corporation by 7.2% in the first quarter. Denver Investment Advisors LLC now owns 22,215 shares of the medical research company’s stock valued at $518,000 after buying an additional 1,500 shares during the period. Finally, Quadrature Capital Ltd purchased a new position in Bruker Corporation during the fourth quarter valued at $244,000. 67.45% of the stock is owned by hedge funds and other institutional investors.
About Bruker Corporation
Bruker Corporation is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. The Company’s segments include Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST).
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.